Association of Progestin Contraceptive Implant and Weight Gain
- PMID: 26855107
- PMCID: PMC11264238
- DOI: 10.1097/AOG.0000000000001289
Association of Progestin Contraceptive Implant and Weight Gain
Abstract
Objective: To evaluate initiation of a two-rod, 150-mg levonorgestrel contraceptive implant on women's perceived and observed body weight.
Methods: We conducted a secondary analysis of data from an open, randomized controlled trial of adult, nonpregnant, human immunodeficiency virus-negative women attending a public clinic in Kingston, Jamaica, who were assigned to initiate implant use either immediately or after a 3-month delay. The primary objective of the parent study was to assess the effect of initiation of the implant on the frequency of condom use. We compared study arms during follow-up using one-sided χ tests for differences in perceived weight gain and loss, one-sided Wilcoxon-Mann-Whitney tests for median gain in measured weight, and logistic regression with generalized estimating equations for risk of gaining greater than 2 kg.
Results: From 2012 to 2014, women were assigned to the implant (n=208) or delay arm (n=206). At 3 months, more women in the implant arm (15.3%) reported perceived weight gain than in the control arm (4.3%) (P=.01). Despite differences in perception, the implant and control arms did not differ significantly in median weight gain at 1-month (0.0 kg and 0.0 kg, respectively; P=.44) and 3-month visits (0.5 kg and 0.0 kg, respectively; P=.27). Study arms did not differ in risk of gaining greater than 2 kg (odds ratio 0.9, 95% confidence interval 0.6-1.3).
Conclusion: We found no evidence of weight gain from short-term implant use. Through the power of the nocebo effect, the practice of counseling women to expect possible weight gain from initiating implant use could lead them to perceive weight gain even in its absence and contribute to the early discontinuation of this highly effective contraceptive method.
Conflict of interest statement
Financial Disclosure
The authors did not report any potential conflicts of interest.
Figures
References
-
- FDA patient labeling: NEXPLANON (etonogestrel implant) radiopaque subdermal. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021529s007lbl.pdf. Retrieved October 9, 2015.
-
- FDA patient labeling: IMPLANON (etonogestrel implant). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021529s004lbl.pdf. Retrieved October 9, 2015.
-
- Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safetyand efficacy of a single-rod etonogestrel implant (implanon): results from 11 international clinical trials. Fertil Steril 2009;91:1646–53. - PubMed
-
- Colditz GA, Willett WC, Stampfer MJ, London SJ, Segal MR, Speizer FE. Patterns of weight change and their relation to diet in a cohort of healthy women. Am J Clin Nutr 1990;51:1100–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
